Taking people in United StatesPhase 3

Long-term study of a daily pill for weight control in adults with diabetes

Tests a daily pill against placebo for long-term weight control in adults with obesity.

Plain-language title generated from the registry record
Registry title: A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Key facts

Where: Albany, Atlanta, Austin, Birmingham, Brooklyn, Burke, Chandler, Charlotte, Chesterfield, City of Saint Peters, Clearwater, Columbus, Des Moines, Durham, Escondido, Farmers Branch, Fayetteville, Fort Myers, Fountain Valley, Greer, Gulfport, Hazelwood, Houston, Iowa City, Jacksonville, La Jolla, Lake Forest, Las Vegas, Lawrenceville, Leesburg, Little Rock, Manassas, Mankato, Meridian, Methuen, Miami, Minneapolis, Missoula, Moore, Morehead City, Nashville, Ocala, Ocoee, Omaha, Pembroke Pines, Philadelphia, Phoenix, Portland, Renton, Ridgeland, Rolling Hills Estates, Salt Lake City, San Antonio, San Diego, Silver Spring, Springfield, St Louis, Suffolk, Sun City West, The Bronx, Tucson, Tulsa, Tustin, Union City, Waterbury, Wichita, Winston-Salem, Woodstock, Wylie, and Yukon, United StatesSee the 70 sites
Phase: Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 79 years old?

Source: NCT07654374, who can take part

Where in United States

AlbanyAlbany, United StatesNot yet recruiting
AtlantaAtlanta, United StatesTaking people
AustinAustin, United StatesTaking people
BirminghamBirmingham, United StatesTaking people
BrooklynBrooklyn, United StatesNot yet recruiting
BurkeBurke, United StatesNot yet recruiting
ChandlerChandler, United StatesTaking people
CharlotteCharlotte, United StatesTaking people
ChesterfieldChesterfield, United StatesTaking people
City of Saint PetersCity of Saint Peters, United StatesTaking people
ClearwaterClearwater, United StatesTaking people
ColumbusColumbus, United StatesNot yet recruiting
Des MoinesDes Moines, United StatesTaking people
DurhamDurham, United StatesNot yet recruiting
EscondidoEscondido, United StatesNot yet recruiting
Farmers BranchFarmers Branch, United StatesTaking people
FayettevilleFayetteville, United StatesTaking people
Fort MyersFort Myers, United StatesTaking people
Fountain ValleyFountain Valley, United StatesTaking people
GreerGreer, United StatesTaking people
GulfportGulfport, United StatesTaking people
HazelwoodHazelwood, United StatesTaking people
HoustonHouston, United StatesTaking people
Iowa CityIowa City, United StatesNot yet recruiting
JacksonvilleJacksonville, United StatesTaking people
La JollaLa Jolla, United StatesTaking people
Lake ForestLake Forest, United StatesNot yet recruiting
Las VegasLas Vegas, United StatesNot yet recruiting
LawrencevilleLawrenceville, United StatesTaking people
LeesburgLeesburg, United StatesTaking people
Little RockLittle Rock, United StatesNot yet recruiting
ManassasManassas, United StatesTaking people
MankatoMankato, United StatesTaking people
MeridianMeridian, United StatesTaking people
MethuenMethuen, United StatesTaking people
MiamiMiami, United StatesNot yet recruiting
MinneapolisMinneapolis, United StatesTaking people
MissoulaMissoula, United StatesTaking people
MooreMoore, United StatesTaking people
Morehead CityMorehead City, United StatesTaking people
NashvilleNashville, United StatesTaking people
OcalaOcala, United StatesTaking people
OcoeeOcoee, United StatesTaking people
OmahaOmaha, United StatesNot yet recruiting
Pembroke PinesPembroke Pines, United StatesNot yet recruiting
PhiladelphiaPhiladelphia, United StatesTaking people
PhoenixPhoenix, United StatesTaking people
PortlandPortland, United StatesTaking people
RentonRenton, United StatesTaking people
RidgelandRidgeland, United StatesTaking people
Rolling Hills EstatesRolling Hills Estates, United StatesTaking people
Salt Lake CitySalt Lake City, United StatesNot yet recruiting
San AntonioSan Antonio, United StatesTaking people
San DiegoSan Diego, United StatesTaking people
Silver SpringSilver Spring, United StatesTaking people
SpringfieldSpringfield, United StatesTaking people
St LouisSt Louis, United StatesTaking people
SuffolkSuffolk, United StatesTaking people
Sun City WestSun City West, United StatesTaking people
The BronxThe Bronx, United StatesTaking people
TucsonTucson, United StatesTaking people
TulsaTulsa, United StatesTaking people
TustinTustin, United StatesNot yet recruiting
Union CityUnion City, United StatesTaking people
WaterburyWaterbury, United StatesTaking people
WichitaWichita, United StatesTaking people
Winston-SalemWinston-Salem, United StatesTaking people
WoodstockWoodstock, United StatesTaking people
WylieWylie, United StatesTaking people
YukonYukon, United StatesTaking people

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Print a page for my doctor

Trial details

Who runs it: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Trial code: NCT07654374
Record updated: 20 October 2026
Original description: This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.Read full original descriptionShow less
A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.
Inclusion: Signed Informed Consent; Have a BMI ≥27.0 kg/m2 at Screening; Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol/mol) to ≤10% (86 mmol/mol) at Screening.
Exclusion: Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening; Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema; Self-reported change in body weight >5 kg (11 pounds) within 3 months before Screening; Have prior or planned surgical or non-surgical treatment for obesity; Have type 1 diabetes, history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2DM.
ClinicalTrials.gov NCT07654374